14 completed, 2 terminated, 2 withdrawn, 1 suspended. 19 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 14, Terminated 2, Withdrawn 2, Suspended 1 |
| Phase 2 | 7 | Completed 6, Suspended 1 |
Follow Tongue Cancer: new trials by email Literature Review of Tongue Cancer trials Research Report on Tongue Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Radiotherapy of Tongue Cancer Using an Intraoral Stent Intraoral stent, No intraoral stent - Tongue Cancer | Phase 1 | Completed | Oslo University Hospital | 13 | 2018-03-09 | 2023-11-03 |
| Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer (18)F-Fluoroazomycin arabinoside, Pimonidazole - Tongue Cancer | Phase 1 / Phase 2 | Suspended | Sunnybrook Health Sciences Centre | 10 | 2018-01-25 | 2024-08-12 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer High-activity natural killer - Tongue Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 20 | 2016-12-01 | 2019-09-12 |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck sorafenib tosylate, cisplatin, docetaxel - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 3 | 2014-04-14 | 2018-05-24 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy entolimod, intensity-modulated radiation therapy, cisplatin - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-01-01 | 2013-12-11 | |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | University of Chicago | 48 | 2013-03-26 | 2024-07-31 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy everolimus, erlotinib hydrochloride, biopsy - Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2011-04-01 | 2023-04-04 | |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. placebo, laboratory biomarker analysis, questionnaire administration - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 70 | 2007-09-04 | 2020-02-20 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Ad5CMV-p53 gene, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oropharyngeal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2003-06-01 | 2013-01-23 |
| Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer erlotinib hydrochloride, docetaxel, radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2002-09-01 | 2014-06-06 |
Tongue Neoplasms (19) · Salivary Gland Neoplasms (12) · Squamous Cell Carcinoma of Head and Neck (12) · Colonic Neoplasms (4) · Mouth Neoplasms (4) · Pancreatic Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Esthesioneuroblastoma, Olfactory (3) · Head and Neck Neoplasms (3) · Laryngeal Neoplasms (3) · Oropharyngeal Neoplasms (3) · Rectal Neoplasms (3) · Stomach Neoplasms (3) · Bile Duct Neoplasms (2)
Mouth Diseases (19) · Neoplasms by Site (19) · Stomatognathic Diseases (19) · Tongue Diseases (19) · Neoplasms (18) · Head and Neck Neoplasms (16) · Carcinoma (15) · Mouth Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Glandular and Epithelial (15) · Salivary Gland Diseases (12) · Carcinoma, Squamous Cell (11) · Digestive System Diseases (6) · Gastrointestinal Diseases (6) · Respiratory Tract Diseases (6)
Cetuximab (5) · Erlotinib Hydrochloride (3) · Cisplatin (2) · Docetaxel (2) · Everolimus (2) · Radiation (2) · Radiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · CBLB502 (1) · Carboplatin (1) · Chemoprevention (1) · Electrophoresis, Polyacrylamide Gel (1) · FPP(RGD)2 (1)
National Cancer Institute (NCI) (4) · Fox Chase Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · University of Chicago (2) · Fuda Cancer Hospital, Guangzhou (1) · Klus Pharma Inc. (1) · Oslo University Hospital (1) · Quadriga Biosciences, Inc. (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1) · Stanford University (1) · Sunnybrook Health Sciences Centre (1) · University of Washington (1)
United States (14) · Australia (1) · Canada (1) · China (1) · Norway (1)
Amit Agrawal (1) · Anurag Singh (1) · Barbara Burtness (1) · Einar Dale, MD PhD (1) · Gary L. Clayman (1) · Heather Wakelee (1) · Ian Poon, MD, FRCPC (1) · Jonas de Souza (1) · Jordi Rodon Ahnert, MD, PhD (1) · Laura Chow (1) · Laura Goff (1) · Matthew Old, MD (1) · Sanjiv Gambhir, MD, PhD (1) · Tanguy Seiwert (1)
PMID 25965900, PMID 26062933, PMID 26611425, PMID 26928328, PMID 30850872, PMID 35945244
N01CM62201 (1), P30CA015704 (1), P30CA068485 (1), P50CA097007 (1), U01CA062502 (1), U01CA099168 (1)